Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	0.55	-54.84	-62.26	-94.66	-122.73
Depreciation & Amortization	12.16	12.07	12.33	12.24	1.88
Stock-Based Compensation	22.37	18.36	10.72	12.16	11.38
Other Adjustments	3.91	-3.76	-1.52	2.52	2.08
Change in Receivables	-10.64	-1.22	-8.37	-13.37	-6.24
Changes in Inventories	-19.29	-8.78	-14.8	-7.47	-7.42
Changes in Accounts Payable	-0.07	-9.61	6.96	-4.32	5.53
Changes in Accrued Expenses	3.31	3.65	-5.86	-11.38	12.56
Changes in Other Operating Activities	16.32	7.14	15.77	1.39	7.43
Operating Cash Flow	28.63	-36.98	-47.02	-102.89	-95.54
Capital Expenditures	-0.7	-0.87	-2.26	-0.52	-1.09
Purchases of Investments	-	-34.49	-43.74	-	-43.02
Proceeds from Sale of Investments	-	40.24	40	34.99	103.6
Other Investing Activities	-	-	-	-	38.47
Investing Cash Flow	-0.7	4.88	-6	34.46	97.96
Long-Term Debt Issued	-	50	-	146.21	-
Long-Term Debt Repaid	-	-	-	-43.5	-
Net Long-Term Debt Issued (Repaid)	-	50	-	102.72	-
Issuance of Common Stock	22.27	1.73	0.58	30.84	27.84
Repurchase of Common Stock	-10.88	-3.73	-1.01	-0.47	-0.53
Net Common Stock Issued (Repurchased)	11.39	-2	-0.43	30.37	27.3
Other Financing Activities	-	-11.83	-1.19	-5.61	-0.05
Financing Cash Flow	11.39	36.17	-1.61	127.47	27.25
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-0
Net Cash Flow	39.32	4.07	-54.64	59.04	29.67
Free Cash Flow	27.93	-37.85	-49.29	-103.42	-96.62
FCF Margin	9.57%	-18.64%	-30.07%	-93.80%	-194.84%
Free Cash Flow Per Share	0.16	-0.26	-0.36	-0.76	-1.22
Levered Free Cash Flow	12.29	-1.24	-50.12	-2	-103.84
Unlevered Free Cash Flow	36.63	-28.71	-31	-90.78	-96.27

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q